Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...

In patients with kidney cancer undergoing surgery, the risk for kidney failure (ESRD) appears no lower with partial kidney removal (nephrectomy).

70.8% of those who were aware of their hypertension status and met criteria for meds had uncontrolled hypertension ...

Break Wave lithotripsy and ultrasonic propulsion are among the investigational noninvasive ultrasound procedures to treat kidney stones.

Weight reduction at 1 year linked to medication active agent, dosage, treatment indication, persistence of coverage ...

(HealthDay News) — The overall second primary malignancy (SPM) point estimate was 5.8% for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study published online in ...

In a UK Biobank study, CMM risk increased with the number of chronic pain sites, and having more pain sites increased risk of T2D, IHD, and stroke.

Medicare has a proposed a 2.8% reduction in its Physician Fee Schedule conversion factors that could put a financial squeeze on independent urology practices.

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Interleukin-6 levels were associated with an increased risk for obesity-related cancer among individuals with newly diagnosed type 2 diabetes.

In recent study, incidence of CTRCD and LVEF 40% were higher in association with high- versus low-risk AI ECG screen. (HealthDay News) — For patients undergoing treatment for certain types of ...

Dual anti-PD1/CTLA-4 therapy with nivolumab plus ipilimumab appears more effective than monotherapy for select patients with mCRPC, but the combination is associated with high toxicity. Dual PD1 ...